Related Experiment Video
Updated: Jul 23, 2026
Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein
Published on: May 30, 2015
S100A12 (EN-RAGE) in monitoring Kawasaki disease
Dirk Foell1, Fukiko Ichida, Thomas Vogl
1Department of Paediatrics, University Hospital Münster, Von-Esmarch-Str 58, 48149, Münster, Germany. dfoell@uni-muenster.de <dfoell@uni-muenster.de>
Insights
The calcium-binding protein S100A12 is linked to Kawasaki disease inflammation. Lowering S100A12 levels may offer new therapeutic strategies for inflammatory conditions.
Area of Science:
- Biochemistry
- Immunology
- Pediatrics
Background:
- S100A12 protein promotes inflammation by interacting with the receptor for advanced glycation end products (RAGE).
- Preclinical studies in mice suggest blocking S100A12 has therapeutic potential.
Purpose of the Study:
- To investigate the association between S100A12 expression and Kawasaki disease activity.
- To evaluate S100A12 as a potential biomarker and therapeutic target in Kawasaki disease.
Main Methods:
- Analysis of S100A12 expression in 31 individuals with Kawasaki disease.
- Monitoring serum S100A12 concentrations before and after intravenous immunoglobulin treatment.
Main Results:
- A significant association was observed between S100A12 expression and Kawasaki disease activity.
- Serum S100A12 levels decreased rapidly (463 to 184 microg/L) within 24 hours in 28 patients responding to gammaglobulin therapy (p<0.0001).
Conclusions:
- S100A12 plays a role in the inflammatory processes of Kawasaki disease.
- S100A12 represents a promising novel therapeutic target for managing inflammatory disorders, including Kawasaki disease.
Abstract:
The calcium-binding protein S100A12 causes inflammation through interaction with the multiligand receptor for advanced glycation end products (RAGE). Blocking of S100A12 showed promising therapeutic effects in mice. We investigated 31 individuals with Kawasaki disease, and recorded an association between expression of S100A12 and activity of Kawasaki disease. Serum concentrations of S100A12 decreased quickly in 28 patients who responded to treatment with gammaglobulin (from 463 microg/L [SD 316] to 184 microg/L [147] within 24 h, p<0.0001). Since the interaction of S100A12 with multiligand receptors has a key role in inflammatory responses, this protein could serve as a novel target for future therapeutic interventions in inflammatory disorders.
